CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 119 enrolled
Drug / intervention
Escitalopram + Celecoxib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02389465
NCT02389465Phase 4Completed

Stress and Inflammation in the Pathophysiology of Late Life Depression

University of Pennsylvania·interventional·Posted Mar 17, 2015·Updated Oct 2, 2023

In Brief

A Phase 4 clinical trial evaluating Escitalopram + Celecoxib and Escitalopram + Placebo for Depression and Inflammation. Completed, enrolled 119 participants across 1 site.

Detailed Summary

Over 18% of Americans aged 65 years and older have depression. Recent evidence suggests that there is a link between depression and inflammatory disease. This study investigates the relationship between inflammation in the brain and depression. Comparing biological and psychological differences in depressed and non-depressed people allows researchers to find better ways to treat and prevent depression. All participants will have: neuropsychological tests, an EKG, a spinal tap, a blood draw, and, if depressed, given either an antidepressant coupled with an anti-inflammatory medication or an anti-depressant coupled with a placebo for six weeks. The investigators are trying to correlate brain function with depression levels and biomarkers from the blood and spinal fluid.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 17, 2015
Enrollment StartAug 1, 2014
Primary CompletionJul 18, 2022
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 11.3 years ago

Interventions

Escitalopram + Celecoxibdrug

Participants will receive celecoxib in addition to escitalopram

Escitalopram + Placebodrug

Participants will receive a placebo in addition to escitalopram.